Scientific Presentations

 2026 AACR: In vivo preclinical efficacy of a novel “payload-bearing” peptide LX-101 targeting IGF-1R in Ewing sarcoma 

​​​

2026 AACR, San Diego, CA (Presentation)

​

 2025 ARVO: LX-101, a Novel Payload-bearing IGF-1 Methotrexate Conjugate, Shows Anti-inflammatory and Anti-fibrotic Effects in Thyroid Eye Disease

​​

2025 ARVO, Salt Lake City, UT (Presentation)

​

 2025 AACR: LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Anti-Tumor Activity in Ewing Sarcoma Animal Models and Desmoplastic Small Round Cell Tumors

​​

2025 AACR, Chicago, IL (Presentation)

​

 2025 AACR: LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Preclinical Anti-Tumor Activity Against Multiple Cancer Types with Elevated IGF-1R Expression

​​

2025 AACR, Chicago, IL (Presentation)

​

 2025 NANOS: LX-101, a Novel Payload-bearing Insulin-like Growth Factor-1 Receptor Targeted Therapy, Inhibits Thyroid Eye Disease Inflammation

​​

2025 NANOS, Tucson, AZ (Presentation)

​

 2025 TAT: LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Preclinical Anti-Tumor Activity Against Multiple Cancer Types with Elevated IGF-1R Expression

​​

2025 TAT, Paris, France (Presentation)

​

 2025 TAT: LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Anti-Tumor Activity in Ewing Sarcoma Animal Models and Desmoplastic Small Round Cell Tumors 

​​

2025 TAT, Paris, France (Presentation)

​

 2024 AACR: LX-101, a Novel, Clinical Stage, Payload-bearing Targeted Therapy Directed to the Insulin-like Growth Factor 1 Receptor (IGF-1R), Demonstrates Potent Preclinical Anti-Tumor Activity Against Multiple Cancer Types with Well-Established Ties to the IGF-1/IGF-1R Pathway

​

2024 AACR, San Diego, CA (Presentation)

​

 2024 ESMO Sarcoma and Rare Cancers: LX-101, a Novel, Clinical Stage IGF-1R Targeted Therapy has Potent Preclinical Activity Against IGF-1R-Related Cancers

 

ESMO 2024 Sarcoma, Lugano, Switzerland (Presentation)

​

 2024 ESMO TAT: LX-101 Demonstrates Activity in Patients With High IGF-1R Tumor Expression 

 

TAT 2024 Paris, France (Presentation)

​

CTOS 2023: LX-101 Demonstrates Potent Preclinical Activity Against Pediatric Sarcomas 

 

CTOS 2023 Dublin, Ireland (Presentation)

​

CWC: LX-101 Demonstrates Potent Preclinical Activity Against a Range of Pediatric Cancers

 

7th Cancer World Congress Palermo, Italy (Presentation)

​